The London conference on neglected tropical diseases (NTDs) held in January was a seminal moment in the global fight against a group of diseases which are often overshadowed in the global health agenda by HIV, malaria and TB.
Sabin President Dr. Peter Hotez's latest editorial, titled “Campaign Spending: What Else Can $2 Billion Buy?” was recently published in the Huffington Post. The editorial discusses how the amount of money spent on this year’s presidential campaign could have also been used to treat and control NTDs in various regions around the world.
See the original article in the Huffington Post here.
The open-access journal, PLoS NTDs, celebrated its fifth anniversary. To commemorate this great achievement, the journal compiled editorials and research papers published over the last five years to create a collection, called “The Geopolitics of NTDs.”
The collection focuses on the geographic distribution of NTDs by region to highlight the key differences as well as similarities between the diseases in different areas around the world.
October 11, 2012 | Financial Times
The Financial Times special report “Combating Neglected Diseases” contains in-depth stories and interviews featuring several of Sabin’s key programs, including Sabin Vaccine Development, the Global Network for Neglected Tropical Diseases and the Dengue Vaccine Initiative.
Read the full report here.
Most people have never heard of diseases like elephantiasis, river blindness, snail fever, trachoma, roundworm, whipworm, or hookworm. But one in six people globally, including more than half a billion children, have these organisms living and breeding inside their bodies.
Yet the solution to these diseases is relatively simple: For only 50 cents, we can provide one person with treatment and protection against all seven NTDs for up to one year.
A lot of people ask us, why is it a Global Network?
Controlling and eliminating the seven most common NTDs is no simple task that can be accomplished by one organization or individual. Successfully fighting these diseases of poverty requires a community effort – and the hard work and dedication of stakeholders at all levels, including pharmaceutical companies, non-profit organizations, governments, academic institutions, corporations and the general public.